WO2010039748A3 - Récepteurs de la neurotoxine botulique e et leurs utilisations - Google Patents

Récepteurs de la neurotoxine botulique e et leurs utilisations Download PDF

Info

Publication number
WO2010039748A3
WO2010039748A3 PCT/US2009/058906 US2009058906W WO2010039748A3 WO 2010039748 A3 WO2010039748 A3 WO 2010039748A3 US 2009058906 W US2009058906 W US 2009058906W WO 2010039748 A3 WO2010039748 A3 WO 2010039748A3
Authority
WO
WIPO (PCT)
Prior art keywords
bont
toxin
cell
polypeptide
receptor
Prior art date
Application number
PCT/US2009/058906
Other languages
English (en)
Other versions
WO2010039748A2 (fr
Inventor
Edwin Chapman
Min Dong
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of WO2010039748A2 publication Critical patent/WO2010039748A2/fr
Publication of WO2010039748A3 publication Critical patent/WO2010039748A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un polypeptide isolé comprenant une séquence d’acide aminé sélectionnée parmi les acides aminés 506-582 de SV2A, où la position 573 est N et est glycosylée, ou parmi les acides aminés 449-525 de SV2B, où la position 516 est N et est glycosylée. L'invention concerne également: un anticorps se fixant spécifiquement audit polypeptide; un acide nucléique isolé comprenant un polynucléotide codant pour ledit polypeptide; une méthode de réduction de la toxicité de la BoNT/E chez un animal; une méthode d’identification d’un agent bloquant ou inhibant la liaison entre la BoNT/E et une protéine SV2A ou SV2B; une méthode de suivi de l’endocytose ou de l'exocytose de la vésicule synaptique; une méthode spécifique d’administration d’une entité chimique à une cellule présentant un récepteur spécifique d’une toxine BoNT; une toxine chimère ciblant le domaine protéolytique d’une toxine sur une cellule, la toxine chimère comprenant un domaine catalytique ou protéolytique de la toxine BoNT, ou ciblant un de ses ligands ou fragments sur un récepteur non BoNT de la cellule; une méthode ciblant le domaine protéolytique d’une toxine BoNT sur une cellule, et sur une cellule non neuronale isolée comportant un récepteur de la toxine BoNT; et sur une méthode de criblage d’un inhibiteur de la toxine BoNT.
PCT/US2009/058906 2008-09-30 2009-09-30 Récepteurs de la neurotoxine botulique e et leurs utilisations WO2010039748A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10142108P 2008-09-30 2008-09-30
US61/101,421 2008-09-30

Publications (2)

Publication Number Publication Date
WO2010039748A2 WO2010039748A2 (fr) 2010-04-08
WO2010039748A3 true WO2010039748A3 (fr) 2010-05-27

Family

ID=41698426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/058906 WO2010039748A2 (fr) 2008-09-30 2009-09-30 Récepteurs de la neurotoxine botulique e et leurs utilisations

Country Status (2)

Country Link
US (2) US8771707B2 (fr)
WO (1) WO2010039748A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458472B1 (fr) * 2016-05-16 2021-10-20 President and Fellows of Harvard College Procédé de purification et d'activation de la neurotoxine botulique
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN112625111B (zh) * 2019-09-24 2023-09-15 四川大学华西医院 突触囊泡蛋白sv2a的制备方法
IL272002A (en) 2020-01-13 2021-07-29 The Israel Institute Of Biological Res Iibr Methods for identifying active compounds against Clostridium neurotoxin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004051222A2 (fr) * 2002-12-03 2004-06-17 Ucb, S.A. Procedes d'identification d'agents destines au traitement de crises epileptiques, maladies neurologiques, endocrinopathies et maladies hormonales

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
DE102005051789B4 (de) * 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004051222A2 (fr) * 2002-12-03 2004-06-17 Ucb, S.A. Procedes d'identification d'agents destines au traitement de crises epileptiques, maladies neurologiques, endocrinopathies et maladies hormonales

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DONG MIN ET AL: "Glycosylated SV2A and SV2B Mediate the Entry of Botulinum Neurotoxin E into Neurons", MOLECULAR BIOLOGY OF THE CELL, vol. 19, no. 12, December 2008 (2008-12-01), pages 5226 - 5237, XP002571458, ISSN: 1059-1524 *
DONG MIN ET AL: "SV2 is the protein receptor for botulinum neurotoxin A", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 312, no. 5773, 28 April 2006 (2006-04-28), pages 592 - 596, XP002423369, ISSN: 0036-8075 *
JANZ R ET AL: "SV2C is a synaptic vesicle protein with an unsually restricted localization: Anatomy of a synaptic vesicle protein family", NEUROSCIENCE, NEW YORK, NY, US, vol. 94, no. 4, 3 November 1999 (1999-11-03), pages 1279 - 1290, XP002405054, ISSN: 0306-4522 *

Also Published As

Publication number Publication date
WO2010039748A2 (fr) 2010-04-08
US20140322730A1 (en) 2014-10-30
US20100104560A1 (en) 2010-04-29
US8771707B2 (en) 2014-07-08

Similar Documents

Publication Publication Date Title
Emmerich et al. Optimising methods for the preservation, capture and identification of ubiquitin chains and ubiquitylated proteins by immunoblotting
EA200970231A1 (ru) СПОСОБ ОЧИСТКИ Fc-СОДЕРЖАЩИХ БЕЛКОВ
ATE393228T1 (de) Fusionsproteine und deren verwendung zur messung von protease-aktivität
WO2007048638A3 (fr) Recepteur de proteine de neurotoxine a de botulinus et utilisations associees
CA2647042A1 (fr) Discrimination d'isoformes de proteines et leurs mesures quantitatives
EA200970230A1 (ru) СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
JP2016026303A5 (fr)
WO2007146944A3 (fr) Protéines dépourvues d'activité catalytique et procédé d'extraction d'enzymes à partir de matériaux d'origine végétale
WO2006057763A3 (fr) Procede de prevision des interactions ligand-recepteur couple aux proteines-g
WO2010091182A3 (fr) Procédés pour cribler des agents candidats pour la modulation de la prorénine et de la rénine, tests de détection de la prorénine, et anticorps qu'ils emploient
ATE541054T1 (de) Bio-barcode erkennung für zielmoleküle
WO2007147159A3 (fr) Ligands fonctionnels de type acide nucléique pour protéines fluorescentes
DK1953551T3 (da) Prion-proteinligander samt fremgangsmåder til anvendelse deraf
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
WO2008060483A3 (fr) Biocapteurs d'interaction protéine-protéine et leurs procédés d'utilisation
DK1607745T3 (da) Ligand til G-proteinkoplet receptor FPRL2 og anvendelser deraf
WO2007008071A3 (fr) Procede de detection et/ou d'elimination d'une proteine et/ou d'un peptide, comprenant une structure croisee $g(b), d'une solution aqueuse comprenant une proteine
JP2009513118A5 (fr)
ATE489623T1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper
WO2010039748A3 (fr) Récepteurs de la neurotoxine botulique e et leurs utilisations
WO2009139601A3 (fr) Procédé et colonne d’affinité pour la purification des protéines
WO2006021584A3 (fr) Purification de polypeptides du facteur xiii a partir de matiere vivante
Fortis et al. A new approach for the detection and identification of protein impurities using combinatorial solid phase ligand libraries
KR101818777B1 (ko) 신경독 폴리펩티드의 양 및 이들의 촉매 활성 및 단백질 분해 활성의 결정수단 및 방법
WO2009086125A3 (fr) Compositions d'acides nucléiques et de protéines à étiquettes d'affinité, et procédés pour leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09748873

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09748873

Country of ref document: EP

Kind code of ref document: A2